Pathos AI raises $237 million to accelerate its cancer treatments
The New York biotech Pathos AI has raised $237 million in a Series E round, for a valuation of about $3 billion. Bristol Myers Squibb leads the operation, while Foundry remains central to the clinical strategy.
Pathos AI, a New York biotech founded in 2022, has closed a $237 million Series E funding round, for a post-money valuation of about $3 billion, according to announcements published on October 23, 2026. Bristol Myers Squibb led the operation, with participation from existing shareholders. The goal is simple: to finance cancer treatments relying on AI, when each clinical trial is costly, time-consuming, and can go off track.
Foundry, the tool that sorts candidates without lifting a finger
The core of the system is called Foundry, an AI platform that Pathos describes as capable of exploiting genomic data, medical records, and clinical results to identify the most promising molecules and the patients most likely to benefit. SiliconANGLE reports the system has access to about 200 petabytes of oncology data. The company also says it uses AI agents to prioritize hundreds of drug candidates, then structure so-called biomarker-driven trials, i.e., guided by biomarkers, biological indicators that help measure treatment effects.
Pathos’s message is clear: improve the probability of success in development programs. Iker Huerga, CEO, summarized it as: "We are building a platform to systematically improve the probability of success in drug development," then "Foundry has fundamentally accelerated our ability to identify highly promising clinical assets and integrate them into our pipeline." The statement reveals much about the logic at work. AI does not make a drug alone; it mainly reduces the number of misplaced bets.
Capital will first serve JSKN016, then other programs
Pathos plans to use this Series E to advance its JSKN016 program, an antibody-drug conjugate designed to target TROP2 and HER3, towards registration studies aimed at producing data necessary for regulatory approval. The company will also fund three other programs: Pocenbrodib, for castration-resistant prostate cancer and relapsed or refractory multiple myeloma; AZD4241, developed with AstraZeneca targeting the estrogen receptor in certain breast cancers; and DO-2, a MET kinase inhibitor for cancers linked to alterations of this protein.
According to Just AI News, the Foundry platform also helps continuously recalculate the probability of success of a program as new clinical data arrives. This approach helps decide whether to continue, adjust, or stop development. In biotechs, knowing when to give up can sometimes be as valuable as a good gamble.
Funding fits into a rapid growth trajectory
The funding announced in October 2026 fits into an already rapid trajectory. Pathos raised $365 million in a Series D round in May 2025, for a valuation of about $1.6 billion, then $62 million in Series C in October 2024, according to Just AI News. Meanwhile, the company expanded its portfolio to four clinical assets. Both sources also agree on one point: the AI focus is not a marketing slogan, but a tool for selecting and guiding trials.
One fundamental question remains, often reminded by researchers: AI still needs to prove its robustness in real conditions, with clinical validation and regulatory oversight. On this front, Pathos is moving fast. But in pharma, speed never replaces evidence.
By the numbers
- $237 million — amount of Series E, October 2026, Pathos AI.
- $3 billion — estimated post-money valuation, October 2026, Just AI News.
- 200 petabytes — volume of oncology data claimed by Pathos, October 2026, SiliconANGLE.
- $365 million — Series D announced in May 2025, according to Just AI News.
- $62 million — Series C raised in October 2024, according to Just AI News.